CBR-5884 是一种磷酸甘油酸脱氢酶抑制剂，IC50为 33 μM。 它抑制癌细胞中的丝氨酸合成，选择性地抑制黑素瘤和乳腺癌细胞系的增殖，对具有高丝氨酸生物合成活性的癌细胞系有选择性毒性。

CBR-5884 is an selective, active of phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 33 μM. CBR-5884 inhibits de novo serine synthesis in cancer cells and is selectively toxic to cancer cell lines with high serine biosynthetic activity. CBR-5884 selectively inhibits the proliferation of melanoma and breast cancer lines that have a high propensity for serine synthesis. Biochemical characterization of the inhibitor revealed that it was a noncompetitive inhibitor that showed a time-dependent onset of inhibition and disrupted the oligomerization state of PHGDH

CBR-5884 (15 or 30 μM; 3-5 days) selectively inhibits breast cancer lines that have a high propensity for serine synthesis. CBR-5884 (15 or 30 μM; 3-5 days) also selectively inhibits the proliferation of melanoma.

681159-27-3

C14H12N2O4S2

336.39

CBR-5884

DMSO:47 mg/mL (139.72 mM),Need ultrasonic
H2O:< 0.1 mg/mL (insoluble)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years